QIBA CT Volumetry Biomarker Ctte (BC) Call
27 February 2017 at 11 AM CT
Draft Call Summary

In attendance:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th>RSNA:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jenifer Siegelman, MD, MPH (Co-Chair)</td>
<td>Rudresh Jarecha, MBBS</td>
<td>Nicholas Petrick, PhD</td>
<td>Joe Koudelik</td>
</tr>
<tr>
<td>Ehsan Samei, PhD (Co-Chair)</td>
<td>Claudia Kirsch, MD</td>
<td>Balu Rajagopalan, PhD</td>
<td>Julie Lisiecki</td>
</tr>
<tr>
<td>Hubert Beaumont, PhD</td>
<td>Yongguang Liang, PhD</td>
<td>Marthony Robins, PhD</td>
<td></td>
</tr>
<tr>
<td>Andrew Buckler, MS</td>
<td>Eleni Liapi, MD, ScM</td>
<td>Na Sun, PhD</td>
<td></td>
</tr>
<tr>
<td>Heang-Ping Chan, PhD</td>
<td>James Mulshine, MD</td>
<td>Ying Tang, PhD</td>
<td></td>
</tr>
<tr>
<td>Charles Fenimore, PhD</td>
<td>Nancy Obuchowski, PhD</td>
<td>Pierre Tervé, MS</td>
<td></td>
</tr>
<tr>
<td>Ritu Gill, MD, MPH</td>
<td>Kevin O’Donnell, MAsc</td>
<td>Binsheng Zhao, DSc</td>
<td></td>
</tr>
<tr>
<td>Lubomir Hadjiiski, PhD</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RSNA:

Jenifer Siegelman, MD, MPH (Co-Chair)
Rudresh Jarecha, MBBS
Nicholas Petrick, PhD
Joe Koudelik
Ehsan Samei, PhD (Co-Chair)
Claudia Kirsch, MD
Balu Rajagopalan, PhD
Julie Lisiecki
Hubert Beaumont, PhD
Yongguang Liang, PhD
Marthony Robins, PhD
Heang-Ping Chan, PhD
James Mulshine, MD
Ying Tang, PhD
Charles Fenimore, PhD
Nancy Obuchowski, PhD
Pierre Tervé, MS
Ritu Gill, MD, MPH
Kevin O’Donnell, MAsc
Binsheng Zhao, DSc
Lubomir Hadjiiski, PhD

Review prior call summary: February 6th summary approved as submitted

Discussion included the following:

**QIDW:**
- Dr. Petrick sent Lungman phantom data and DRO digital sphere data to Dr. Erickson for upload to the QIDW
- No timeline was specified; Dr. Petrick will follow up with Dr. Erickson to let team members know when data is available for download

**Feasibility Test Results (Section 4.4):**
- Dr. Liang reported on feasibility test results from Columbia
  - All results were below the requirements
  - Test completion time was much shorter than anticipated
  - Some questions remained regarding the size of the lesions
    - Some clarifying text may be needed
- Dr. Fenimore also intends to test the CT 233 software to check for reasonable levels of agreement and plans to have results by the next call
- Dr. Gill performed segmentations but had some trouble in interpreting the written instructions/documentation
  - She plans to simplify the instructions for other users
  - Drs. Kirsch and Tang will review the revised instructions and provide user feedback if needed
  - Feedback from all BC members is welcome
- Results from Rush/U Chicago will be discussed on the next call if Dr. Supanich is available

**Action items:**
- Awaiting feasibility results from Dr. Supanich (Rush)
- Columbia experiment questions will need to be reviewed
- Dr. Fenimore to provide results of CT 233 testing on next call
- Dr. Gill to rewrite a segment of the protocol instructions; to be reviewed by Drs. Kirsch and Tang
- Dr. Petrick to follow up with Dr. Erickson regarding QIDW Lungman Phantom data upload
  - Once uploaded, RSNA staff will send notification to the group that the data is available
- Feasibility testing participants will report back to the group with their progress on the next WebEx call
- Additional spreadsheets for a regression module as well as for the coordinates for the RIDER tumors are being compiled by Mr. Tervé

Next Call:  Monday, March 6, 2017 at 11 am CT – (Biomarker Committee)